帕金森病是一種常見的神經(jīng)系統(tǒng)退行性疾病，多發(fā)于60歲以上老年人。發(fā)病機制為中腦黑質(zhì)多巴胺能神經(jīng)元發(fā)生變性進而死亡，從而進一步導(dǎo)致紋狀體多巴胺含量顯著減少而致病。匹莫范色林（pimavanserin）是由美國阿卡迪亞制藥（ACADIA Pharmaceuticals）開發(fā)的抗帕金森精神病的新藥，為5-羥色胺2A受體（5-HT2A）的強力選擇性抑制劑，主要用于幻覺和錯覺等帕金森精神病癥狀的治療。綜述匹莫范色林的化學(xué)性質(zhì)、藥理作用、臨床試驗、不良反應(yīng)等研究情況。

Parkinson's disease is a common degenerative disease of the nervous system, which over sixty years of age people prone to. The pathogenesis is degeneration and death of midbrain substantia nigra dopaminergic neurons, which further leads to the decrease of dopamine content in the striatum. Pimavanserin was a drug developed by Acadia Pharmaceuticals to treat Parkinson's psychiatric symptoms, which is a serotonin 2A receptor (5-HT2A) strongly selective inhibitor. It mainly used for the treatment of Parkinson's psychiatric symptoms such as hallucinations and delusions. In this paper, the chemical properties, pharmacological effect, clinical trials, adverse effects, and other aspects of pimavanserin were reviewed.